Clik here to view.
Medicare negotiations have concluded. What's next for court cases against the...
Multiple drugmakers say they are sticking with their legal strategies against the Inflation Reduction Act even though they agreed to negotiated prices for their therapies. The Centers for Medicare...
View ArticleUnpacking IRA price negotiations results; Lykos’ tough week; Genentech...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleQ&A: Lilly’s top scientists on genetic medicine ambitions, and how they’re...
Last week, Eli Lilly opened the doors of its new research center in Boston, largely focused on genetic therapies. While the Indianapolis-based drugmaker’s $875 billion valuation largely stems from its...
View ArticleAvidity’s upsized $345M offering; Janus Henderson’s new $150M biotech fund
Plus, news about Phathom and CANbridge: Avidity Biosciences closes $345.1M offering: The raise comes on the heels of Phase 1/2 data earlier this month that showed its RNA drug candidate generated a 25%...
View ArticleBioNTech, MediLink to resume trial enrollment for HER3 antibody-drug...
The FDA on Thursday lifted a partial clinical hold on an early-stage study of a HER3-targeting antibody-drug conjugate that BioNTech is developing with China-based MediLink Therapeutics. The hold,...
View ArticleClik here to view.
Walgreens nabs $100M BARDA partnership to expand decentralized clinical trials
Walgreens has snagged US government funding to expand its clinical trial capabilities, continuing investment where others have dropped off. The retail pharmacy is partnering with the US Biomedical...
View ArticleLiquidia scores only tentative approval for Yutrepia due to Tyvaso exclusivity
Liquidia’s stock $LQDA plummeted nearly 30% on Monday following the company’s announcement that while the FDA had granted a tentative approval for its treprostinil inhalation powder, it won’t get final...
View ArticlePfizer brings Indian generics maker to court over Xeljanz patent
Pfizer filed suit against an Indian pharmaceutical company on Friday over its application to market generic versions of Xeljanz XR. Xeljanz XR is an extended-release version of Pfizer’s blockbuster JAK...
View ArticleHalf of IRA negotiation savings to come from three drugs, Brookings finds
For the first 10 drug prices negotiated under the Inflation Reduction Act, about one-half of the estimated $6 billion in Medicare savings is the result of negotiations for just three of those drugs,...
View ArticleClik here to view.
Updated: Eli Lilly's tirzepatide wins in Phase 3 pre-diabetes trial
After recently reporting soaring sales of its diabetes franchise, Eli Lilly is back with more data on its GLP-1/GIP dual agonist tirzepatide. In a Phase 3 trial, the drug reduced the risk of developing...
View ArticleMerck exercises option on one Kelun ADC, returns another as it tweaks broad deal
More than two years into its partnership with China’s Kelun-Biotech, Merck has made further choices on which part of the sprawling early-stage pipeline it wants to move forward. The pharma giant will...
View ArticleClik here to view.
J&J buys another medtech company, this time paying $600M upfront for...
In its fifth acquisition of the year, Johnson & Johnson is again tapping into the medical technology field, which has become a bigger part of its business. The New Jersey healthcare conglomerate...
View ArticleClik here to view.
TCGX and JPM help Pathalys raise $105M to go up against Amgen in subset of...
North Carolina biotech Pathalys Pharma expects to do a rare thing with its nine-figure Series B: file for FDA approval. Whereas most Series B financing rounds get a biotech into Phase 1 or through...
View ArticleBig employers are spending even more money on pharmacy costs, driven by...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Pharmacy costs are taking up a bigger chunk of employers’ total healthcare spending as popular GLP-1...
View ArticleKymera seeks to raise $225M; Adcendo, Multitude's new ADC deal
Plus, news about Talus Bioscience, Moleculin, Organon and Eli Lilly: Kymera Therapeutics aims to raise $225M: The public offering will be used to fund Kymera’s pipeline, and some funds could be used...
View ArticleHouse lawmakers call on FDA to investigate clinical trials run alongside...
A group of bipartisan representatives called on the FDA to play an “active role” in ensuring the US “remains ahead” of China in biotech and urged the regulator to investigate clinical trials conducted...
View ArticleEmergent joins broader efforts for mpox vaccine drive in Africa
Certain pharma companies, governments and public health agencies have separately pledged to help build up vaccine supply in Africa to address the mpox outbreak. Emergent BioSolutions on Monday said it...
View ArticleFTC backs FDA plan to remove switching study requirement for interchangeable...
The Federal Trade Commission is backing a recent FDA proposal to officially remove the requirement that biosimilar developers must run switching studies to obtain interchangeability designations....
View ArticleLawsuit alleges Biogen schemed with PBMs to preserve Tecfidera market
A lawsuit filed against Biogen last week alleges the company participated in a kickback scheme with pharmacy benefit managers to promote its blockbuster multiple sclerosis drug Tecfidera instead of...
View ArticleClik here to view.
J&J scores approval for Rybrevant combo in first-line lung cancer, stoking...
Johnson & Johnson scored a label expansion for Rybrevant in combination with the newly-approved Lazcluze to treat certain first-line lung cancer patients, putting it in direct competition with...
View Article